

The Australasian Registry of Rare and Genetic Kidney Disease (ARRK)

PROTOCOL

1. INTRODUCTION/BACKGROUND INFORMATION

1.1 LAY SUMMARY

The purpose of this project is to establish a national patient registry for children and adults with kidney disease with an emphasis on rare (< 1 in 2000) and genetic diseases. The registry describes a secure online database fronted by a website. The website will be known as the Australasian Registry of Rare and Genetic Kidney Disease (ARRK). The purpose of the registry is to build cohorts and collect detailed clinical information of patients who have a rare or genetic kidney disease from throughout Australia and New Zealand, in order to facilitate research into those disorders. As a secondary objective, the website will also provide a single access point for information written by local experts describing the conditions and up to date information on current research and therapeutics, which will be accessible by the public.

Patients with a kidney disease will be asked by their treating local team whether they would like to participate in this study. Patients with kidney disease will be given an information sheet about the registry and asked for consent to participate in this study. Participants will be given access to the website by using a personalised login to access their own clinical information, and will have access to webpages with information and links about their kidney disease. Participants will have the opportunity to ask their local team any questions and their local team will discuss the research and results of the study with them at a standard clinical appointment. Their clinical data will be uploaded to the registry by the local health team. The information collected will include clinical data from presentation through to therapeutic intervention and the progression of disease to date. All data will be stored on a secure website and be link-anonymised. A patient's data will only be accessible by themselves using their two-part password, their treating team and the ARRK registry-working group (who support the development of the registry website).

The information collected from individual patients will be analysed together with other participants from throughout Australasia who have the same condition. It is envisaged that there will be groups undertaking secondary research studies, who will seek separate ethical approval and separate consent that may also analyse the data in combination with other studies of the disease.

This study will benefit the participants, as it will allow them access to information about their kidney disease from one centralised location, the ARRK website. These information pages will also be available to the public and to health professionals for more detailed information about specific rare and genetic kidney diseases.

1.2 INTRODUCTION

The purpose of ARRK (The Australasian Registry of Rare and Genetic Kidney Disease) is to facilitate translational and epidemiological research into rare and genetic kidney disease by

setting up and maintaining comprehensive clinical databases in partnership with disease-specific research groups.

ARRK will facilitate the identification of well-characterised cohorts of patients who will be invited to participate in clinical trials, development of biomarkers, phenotype-genotype correlations, or outcome studies. It will inform the development of clinical guidelines for specific rare diseases and it will audit treatment and outcome.

ARRK will be able to feedback relevant information to registered patients, and allow patients to provide information including their own reported quality of life and outcome measures.

The expected outcomes for this program for the first 12 months are to recruit up to 80 participants with rare or genetic kidney disease, and collect detailed phenotyping of these patients, form a working group for specific disease categories and provide information pages on the website relevant to participants, their families and health professionals.

1.3 BACKGROUND INFORMATION

The Burden of Rare Disease

Chronic Kidney Disease accounts for a large (and increasing) proportion of national morbidity and mortality. It is increasingly recognised that rare disease similarly contributes disproportionately. 1 in 17 people will be affected by rare disease in their lifetime, there are now over 6700 listed in Orphanet, (the international register of rare diseases) of which approximately 150 are renal. In fact, and accounts for over 50% of children and 8% of adult entering the kidney replacement program. Over 80% of rare disease has an identified genetic origin and in Australian children, genetic kidney disease is prevalent at 70.6/million and accounts for over 10% of Chronic Kidney Disease (CKD) in Australia overall. The health burden from rare kidney disease is consequently significant and Australasians with rare renal disease contribute disproportionately to the national health burden. However, patients with rare disease commonly suffer distinct difficulties in healthcare: namely, difficulty in obtaining a diagnosis, (on average it takes 7.6yrs in the USA and 5.6yrs in the UK); lack of clear and useful information, difficulty in accessing clinical expertise, limited patient support groups and minimal engagement with research, particularly clinical trials.

The role of a patient registry

Conversely, over the last decade, there has been a significant unravelling of the genetic aetiology and molecular pathways involved in the pathogenesis of rare disease. And yet, for all the rare conditions affecting the kidney, less than a handful of therapeutic interventions exist. If we consider how the nephrology community might improve this situation, then we can look to patient registries. Identified globally as a mechanism to enable progress in the care of rare disease, a registry provides a platform, not just for the purpose of patient recruitment; but also provides access to improved information for patients and their families; information for health providers; a portal to access patient support; expert guidelines and enables observational research.

Existing renal registries

Large renal registries exist worldwide: for instance RenalRadar in the UK (Dr Hugh McCarthy - involved in establishment), Podonet in Europe and Neptune in the USA. Furthermore, EuRenomics is a project driven by the European Union with incredible resources to investigate genomics of rare renal disease. And yet, despite the size and funding, these projects do not work in isolation but collaborate extensively in order to strengthen the collective output. They would be open to collaborating with an Australian partner. A good example of such a model is the Australian National Duchene Muscular Dystrophy Registry and how it feeds data into, and collaborates with, the very successful TREAT-NMD global network.

2. FUNDING AND RESOURCES

2.1 SOURCES OF FUNDING

Australia and New Zealand Society of Nephrology (ANZSN) Enabling Grant (\$45,000 June 2015). Further funding is currently being sort from other academic institutions.

3. GOVERNANCE

The day to day running of the registry will be undertaken by a working party which will be an executive voted in for three years. It must include representation from at least three states or territories, a paediatric and adult nephrologist, a clinical geneticist and a patient representative.

The working party will report to the paediatric association of the national body representative of clinical nephrology, The Australian and New Zealand Society of Nephrology. A written report will be provided annually.

4. STUDY OBJECTIVES

4.1 RESEARCH QUESTION

The hypothesis to be tested is: A national/regional patient registry will facilitate research into rare and genetic kidney disease by the development of cohorts of patients with specific kidney diseases to be identified for future research. In addition it will provide a single access point of information for patients, their families and treating clinicians.

4.2 PRIMARY OBJECTIVES

The project aims of the Australasian Registry of Rare and Genetic Kidney Disease (ARRK) are to:

- 1) Provide a centralised IT infrastructure from which multiple separate disease cohorts may develop.
- 2) Collect high quality phenotypic information on recruited patients using software tools, which prioritise global ontology and interoperability with international partners.
- 3) Promote research into all aspects of rare renal disease utilising the cohorts.
- 4) Promote collaboration where appropriate with international registries/studies and industry.

- 5) Develop a linked web-based information resource for patients, families and health professionals living or managing patients with rare/genetic renal disease.
- 6) Provide an educational tool for renal health professionals into basic clinical genetics particularly in regard to nephrology and access to diagnostic tools.

4.3 SECONDARY OBJECTIVES

Secondary objectives include;

- 1) Identify potential Disease Specific Research Groups in Australasia and promote development of new studies.
- 2) Allow participation of Australasian patients in large international cohorts.
- 3) Promote the direct involvement of the renal community in designing a plan for rare kidney disease in Australasia.
- 4) Identify long term funding source to maintain registry as an integral part of clinical care.

4.4 OUTCOME MEASURES

ARRK is a patient registry designed to build cohorts to stimulate secondary research.

Therefore the outcome measurements will include (per year):

- 1) Quantifying the number of recruited patients for the ARRK registry
- 2) Quantifying the number of renal centres or hospitals involved in the recruitment of patients
- 3) Number of researchers requesting cohorts of patients for further research
- 4) Number of disease specific working groups established providing information to the registry
- 5) Academic output including publications of work in which ARRK was utilised
- 6) Number of hits on the ARRK website as a measure of the success of the information pages

5. STUDY DESIGN

5.1 STUDY DESIGN DIAGRAM

Disease Specific Research Groups (DSRGs) have been identified and are planning secondary research studies, which include original work in addition to collaboration with international registries. Supplementary funding is again, being sought for these secondary research studies.

The working party will oversee the running of the website and database. It will work directly with the web development team to optimise the layout and ease of data collection. The web design has been developed in conjunction with the Rare Disease Registry Framework (RDRF) (Centre for Comparative Genomics, Murdoch University, WA) and the database will be held encoded on their secure server, which is already in use for the long-term storage of patient registry data and genetic results.

The registry will promote the formation within Australasia of Disease Specific Research Groups (DSRGs) to design and implement secondary research projects. The DSRGs will seek separate funding and ethical approval but will use the data from this project (ARRK). In order to use the registry data, the DSRGs will comply with a standard operating procedure and will be given the data in a link-anonymised format so that patients are identifiable only by a unique ARRK number.

Furthermore, with consent, information will be transferred between ARRK and ANZDATA (The Australian and New Zealand Dialysis and Transplantation Registry). ANZDATA is a well-established database storing information on all adult and paediatric patients in the end stage renal failure program and has been running for many years. It is an excellent source of information and is therefore sensible for the two databases to be able to operate together and harmonise data transfer to prevent replication of work and maximising the possible analysis of the data that is collected.

The ARRK website is in development currently and as based on a design already in use, there is limited software development. Therefore, once ethical approval is given, patient recruitment will begin within two months and it is envisaged that within a further 6 months the registry will have recruited 80 participants. It will continue to grow in the following twelve months with an expected 200 further participants per year. It is envisaged that the registry will be adopted into routine practice to ensure that patients are provided with an opportunity to participate in research and access to a novel information source.

The patients will be given a unique identifying number on entry. Their data will be “link-anonymised” if shared with international partners. Any information sharing will be governed by the registry working-group following review of the partner contracts.

This protocol is not initially intended to be used towards a student project, although it may be utilised in the future for such a purpose.

5.3 STANDARD CARE AND ADDITIONAL TO STANDARD CARE PROCEDURES

This study is an observational study and will not compare different care procedures and participation (or not) will have no effect on a participant’s medical treatment.

5.4 RANDOMISATION

As this is a cohort study collected the same data from each participant, there is no randomisation required.

5.5 STUDY METHODOLOGY

Patient Recruitment and Consent

A call for recruitment to the registry for patients with a specific disease will be announced via the ANZSN. Local teams will identify those patients who may be eligible. Eligible patients will be invited to participate in the study, they will be provided with an information sheet and the details of the study will be explained to them. Participants may be contacted by post and a letter of invitation with the study information sent to them prior to their consultation. The local teams will then consent the patient.

Data Entry

The website will have generic dataset collection page as well as disease specific datasets to be collected. The data will be manually loaded by the local clinical team. The data to be collected for this study will include patient identifiers and demographic information. Patient identifiers include name, DOB, address, telephone number, treating unit and lead clinician, and Medicare number. Demographic data will include ethnicity, disease, date of onset, date of diagnosis, clinical characteristics, family history, imaging results, pathology results (blood, tissue and genetic), growth parameters and treatment details (medical and non-medical). At a later time-point quality of life will be assessed for participants using an online questionnaire

Data Storage

The website and database will be housed on a secure database system currently used by clinical researchers (Rare Disease Registry Framework (RDRF), Centre for Comparative Genomics, Murdoch University, WA) . Data will be encrypted for transfer and security of the data and will use the current protection standards used by the Department of Health (DOH), NSW.

Data Access

The data will be link-anonymised. There will be different access to the website according to the user type;

Public access will include the information pages for patients/families and general front pages but no clinical information on the participants.

For patients recruited to the registry, they will be able to access their own clinical information with a personalised login, which requires two identifiers. They will not be able to change their information, although they will be able to highlight any potential errors. In the future, they will also be data entry pages for patients, to include quality of life and health outcomes but not clinical data.

For health professionals they will again require personalised login with two identifiers which will enable them to see only the patients in their unit as directed according to the local lead.

The registry working-group will have administration rights allowing them to see total patients recruited and access the admin site.

Disease Specific Research Group once a contract is agreed will have access to a disease specific cohort of patient details, who have consented. The DSRG will not be able to amend the data.

Data Sharing

The local clinical team will have access to view and amend the data of their own patients. The working party will have administration rights and will be able to view the data of all participants recruited.


If the patient consents to sharing of data between ARRK and ANZDATA, the data will be harmonised using multiple cross identifiers to link.

Data collected for patients who have consented to a secondary research study run by an ARRK DSRG will be shared with the research group according to the standard operating procedure which allows them access to the specific disease cohort to view but not amend the data entered.

Should research groups wish to collaborate with international partners, the data may be shared with an international registry in a link-anonymised format such that the ARRK will be able to re-identify but the international partner will not, unless the patient specifically consents to sharing of identifiers with an international partner.

Patient Contact Time Points

Flowchart specifying visits and possible interventions



Informatics

The website will also have a publically accessible information section. This will include both generic and disease specific information for patients and their families and also more specific information for clinicians. It will also provide a description of current research occurring globally. Links will be provided to generic kidney/genetic disease, and more disease specific support groups.

6. STUDY POPULATION

6.1 RECRUITMENT PROCEDURE

A DSRG will be proposed and membership advertised via the weekly newsletter of the ANZSN. Following formation, the DSRG will agree a contract as defined within the Standard Operating Procedure for working with ARRK. A call will then be generated to practising nephrologists with Australia and New Zealand to begin actively recruiting participants with a specific disease to the registry.

All patients within the diagnostic and inclusion criteria will be eligible. A local team will identify with the patient cohort and approach, inform and consent as described above and enter the participant details into the website. This will generate a unique identifying number for the participant. A password will also automatically be generated which will be sent to the participant via email and will then allow them to register and view their clinical details.

Regular reminders for identification and recruitment will be sent via the ANZSN to practising clinicians.

6.2 INCLUSION CRITERIA

Participant inclusion criteria will include the following:

- Children or Adults Aged 0-80 years
- With a diagnosed kidney disease with emphasis on rare (< 1 in 2000) or genetic disease
- At participating hospitals/sites listed
- In which a disease group (national) shows interest in a secondary research project on this rare or genetic kidney disease

6.3 EXCLUSION CRITERIA

Participant exclusion criteria will include;

- Declination to participate in the study
- Inability to obtain informed consent from the child, parent or guardian
- Inability to understand English and there is an absence of an available interpreter

6.4 CONSENT

Consent to participate in this study will be required from the patient or if a child, their parent or guardian. Children 16 years or over can provide consent without a parent/guardian, although it will be advised that they seek advice from their trusted adult. Children 14-16 years can provide implied consent (assent) in the presence of their parent/guardian.

Appropriate parent/patient consent forms will advise of de-identification of data, the use of clinical and demographic data in research, consent to re-contact patients for inclusion in future research through the registry, and instruction on how to withdraw at any time. The consent form will also contain contact information for the registry working-group.

6.5 PATIENT CONTACT

The project will not involve any home visit. Contact will be made with the potential participants either during the process of a routine clinical service, or via written letter of invitation by mail or by a member of the local clinical team by telephone.

7. PARTICIPANT SAFETY AND WITHDRAWAL

7.1 RISK MANAGEMENT AND SAFETY

Participant safety is paramount and will be appropriately considered in this study. Participants in this study will not be subjected to any physical distress.

Participants will be asked to consider their quality of life and will have access to their clinical information, which may invoke psychological distress.

Participants who have concerns over their participation in this study and any psychological symptoms associated with obtaining knowledge from this study will have the ability to consult their treating nephrologist to discuss any issues.

7.2 ADVERSE EVENT REPORTING

As this is a cohort study and observational, there is no risk of an adverse event arising.

7.3. HANDLING OF WITHDRAWALS

The patient information sheet will inform all participants of their right to withdraw from the study at any point in time. If the patient withdraws from the study, their information will be frozen (hidden from recruiting centre) and their data will not be passed onto secondary study unless the participant consents to this.

7.4 CONTINGENCY PLAN

The database is made as secure as possible. If there is a suggestion of a data breach, the protocol in place at Murdoch University will be followed ensuring a rapid response. A policy of open disclosure will be maintained. If funding should cease and the study not be maintained, the data will be held for a period of time according to the guidelines of the NHMRC. Then it would be destroyed.

7.5 REPLACEMENTS

This is an ongoing study, and recruitment of patients will continue.

8. STATISTICAL METHODS

8.1 SAMPLE SIZE ESTIMATION & JUSTIFICATION

The study is an observational study on many different conditions and as such no power calculations or pre study analysis has been undertaken. Statistical analysis of the data will be undertaken in secondary projects under separate ethics proposals.

8.2 POWER CALCULATIONS

N/A

8.3 STATISTICAL METHODS TO BE UNDERTAKEN

N/A

9. STORAGE OF BLOOD AND TISSUE SAMPLES

No samples will be collected or stored in this study.

10. DATA SECURITY & HANDLING

10.1 DETAILS OF WHERE RECORDS WILL BE KEPT & HOW LONG THEY WILL BE STORED

The website and database will be housed on a secure database system (Rare Disease Registry Framework (RDRF), Centre for Comparative Genomics, Murdoch University, WA).

Data collected for this study will include;

1. Patient identifiers include name, DOB, address, telephone number, treating unit and lead clinician, and Medicare number.
2. Demographic data will include ethnicity, disease, date of onset, date of diagnosis, clinical characteristics, imaging results, pathology results (blood, tissue and genetic), growth parameters and treatment details (medical and non-medical).
3. Quality of life will be collected at a later time-point using an online survey

All records from this study will be kept for a minimum of 7 years post study closure.

10.2 CONFIDENTIALITY AND SECURITY

All data will be housed on a secure database system (Rare Disease Registry Framework (RDRF), Centre for Comparative Genomics, Murdoch University, WA)

All data will be encrypted for transfer and security of the data will use the current protection standards used by the Department Of Health, NSW.

11. REFERENCES

APPENDICES

1. ASSOCIATED DOCUMENTS

Document Name	Version Number	Date
Letter of Invitation	v1.2	30/11/2015
Participant Information Sheet - Adult	v1.3	30/11/2015
Participant Information Sheet – Parent/Guardian	v2.3	30/11/2015
Participant Information Sheet - Adolescent	v3.3	30/11/2015
Participant Information Sheet - Child	v4.3	30/11/2015
Participant Consent Form - Adult	v2.3	30/11/2015
Participant Consent Form – Parent/Guardian	v1.3	30/11/2015
Participant Ascent Form - Adolescent	v3.3	30/11/2015
Withdrawal of Consent	v1.3	30/11/2015
ANZSN Enabling Grant Letter		

2. GLOSSARY OF ABBREVIATIONS & TERMS

Abbreviation	Description (using lay language)
ANZDATA	Australia and New Zealand Dialysis and Transplant Registry
ANZSN	Australian and New Zealand Society of Nephrology
ARRK	Australasian Registry of Rare and Genetic Kidney disease
CHW	The Children’s Hospital at Westmead
DOH	Department of Health
DSRG	Disease Specific Research Group
MCH	Monash Children’s Hospital
NEAF	National Ethics Application Form
PMH	Princess Margaret Hospital for Children
RAH	Royal Adelaide Hospital
RBWH	Royal Brisbane and Women’s Hospital
RCH	Royal Children’s Hospital Melbourne
RMH	The Royal Melbourne Hospital
SCH	Sydney Children’s Hospital
TCH	The Canberra Hospital
WH	Westmead Hospital

3. STUDY SITES

Contact Person unless otherwise stated:

Dr Hugh McCarthy

Tel. 02 9845 0000

Email: hugh.mccarthy@health.nsw.gov.au

SITE	ADDRESS	CONTACT PERSON
1. The Children's Hospital at Westmead (CHW)	Cnr Hawkesbury Road and Hainsworth St Westmead NSW 2145	Dr Hugh McCarthy hugh.mccarthy@health.nsw.gov.au 02 9845 0000 Professor Stephen Alexander stephen.alexander@health.nsw.gov.au 02 9845 0000
2. Sydney Children's Hospital (SCH)	High St Randwick NSW 2031	Dr Hugh McCarthy hugh.mccarthy@health.nsw.gov.au 02 9845 0000
3. Westmead Hospital (WH)	Cnr Hawkesbury Rd and Darcy Rd Westmead NSW 2145	Dr Hugh McCarthy hugh.mccarthy@health.nsw.gov.au 02 9845 0000
4. The Canberra Hospital (TCH)	Yamba Drive Garran ACT 2605	Dr Jeffery Fletcher Jeffery.fletcher@act.gov.au 02 6244 2222
5. Royal Brisbane and Women's Hospital (RBWH)	Butterfield St, Herston QLD 4029	Dr Andrew Mallett andrew.mallett@gmail.com 07 3646 8576 Dr Chirag Patel chirag.patel2@health.qld.gov.au 07 3646 1686
6. The Royal Children's Hospital Melbourne (RCH)	50 Flemington Rd, Parkville, VIC 3052	Dr Cathy Quinlan cathy.quinlan@mcri.edu.au 03 9345 5054
7. The Royal Melbourne Hospital (RMH)	34-54 Poplar Road, Parkville, VIC 3052	
8. Royal Adelaide Hospital (RAH)	North Terrace, Adelaide SA 5000	
9. Princess Margaret Hospital for Children (PMH)	Roberts Road, Subiaco, WA 6008	
10. Monash Medical Centre	Clayton Rd Clayton VIC 3186	
11. Dubbo Base	Myall St	

Hospital	Dubbo NSW 2830	
12. Prince of Wales Hospital	Barker St Randwick NSW 2031	
13. St George Hospital	Gray St Kogarah NSW 2217	
14. St Vincent's Hospital	Victoria St Darlinghurst NSW 2010	
15. Wollongong Hospital	Crown St Wollongong NSW 2500	
16. Gosford Hospital	Holden St Gosford NSW 2250	
17. Lismore Base Hospital	Uralba St Lismore NSW 2480	
18. Manning Base Hospital	York St Taree NSW 2430	
19. Mater Misericordiae Hospital	Rocklands Rd North Sydney NSW 2060	
20. Mayo Private - Taree	Potoroo Dr Taree NSW 2430	
21. Newcastle Nephrocare	Bird St Newcastle NSW 2940	
22. Port Macquarie Base Hospital	Wrights Rd Port Macquarie NSW 2444	
23. Royal North Shore Hospital	Reserve Rd St Leonards NSW 2065	
24. Port Macquarie Private Hospital	Lake Road Port Macquarie NSW 2444	
25. Liverpool Hospital	Elizabeth St & Goulburn St Liverpool NSW 2170	
26. Royal Prince Alfred Hospital	Missenden Rd Camperdown	

	NSW 2050	
27. Sydney Adventist Hospital	Fox Valley Rd Wahroonga NSW 2076	
28. Tamworth Hospital	Dean St North Tamworth NSW 2340	
29. The Tweed Hospital	Powell St & Florence St Tweed Heads NSW 2485	
30. Nepean Hospital	Derby St Kingswood NSW 2747	
31. Orange Base Hospital	Forest Rd Orange NSW 2800	
32. The Alfred Hospital	Commercial Rd Prahran VIC 3181	
33. Austin Hospital	Studley Rd Heidelberg VIC 3084	
34. Bendigo Hospital	Barnard St Bendigo VIC 3550	
35. Epworth Hospital	Bridge Rd Richmond VIC 3550	
36. Geelong Hospital	Bellerine St Geelong VIC 3220	
37. St Vincent's Hospital	Victoria Parade Fitzroy VIC 3065	
38. Adelaide Women's and Children's Hospital	72 King William Rd North Adelaide SA 5006	
39. The Queen Elizabeth Hospital	28 Woodville Rd Woodville South SA 5011	
40. Flinders Medical Centre	Flinders Drive Bedford Park SA 5042	
41. Wesley Private Hospital	451 Coronation Drive Auchenflower QLD 4066	
42. Toowoomba	280 Pechey St	

Hospital	Toowoomba QLD 4066	
43. The Townsville Hospital	100 Angus Smith Drive Douglas QLD 4814	
44. Nambour General Hospital	Hospital Rd Nambour QLD 4560	
45. Nambour Selangor Private Hospital	62 Netherton St Nambour QLD 4560	
46. Caloundra Private Hospital	West Terrace Caloundra QLD 4551	
47. Rockhampton Base Hospital	Canning St Rockhampton QLD 4700	
48. Princess Alexandra Hospital	237 Ipswich Rd Woolloongabba QLD 4102	
49. Mackay Base Hospital	475 Bridge Rd Mackay QLD 4740	
50. John Flynn Hospital	42 Inland Dr Tugun QLD 4224	
51. Hervey Bay Hospital	Urraween Rd & Nissan Street Pialba QLD 4655	
52. Greenslopes Private Hospital	Newdegate St Greenslopes QLD 4120	
53. Gold Coast Hospital	1 Hospital Rd Southport QLD 4215	
54. Lady Cilento Children's Hospital	501 Stanley St South Brisbane QLD 4101	Dr Andrew Mallett andrew.mallett@gmail.com 07 3646 8576 Dr Chirag Patel chirag.patel2@health.qld.gov.au 07 3646 1686
55. Cairns Base Hospital	165 The Esplanade Cairns City QLD 4870	
56. Bundaberg Base Hospital	271 Bourbong St Bundaberg	

	QLD 4670	
57. Allamanda Private Hospital	21 Spendelove Ave Southport QLD 4215	